Implications of immune cells in oncolytic herpes simplex virotherapy for glioma

被引:0
作者
Yoshihiro Otani
Ji Young Yoo
Toshihiko Shimizu
Kazuhiko Kurozumi
Isao Date
Balveen Kaur
机构
[1] Okayama University Graduate School of Medicine,Department of Neurological Surgery
[2] Dentistry,Department of Neurosurgery
[3] and Pharmaceutical Sciences,Department of Neurosurgery
[4] McGovern Medical School,Department of Neurosurgery
[5] University of Texas Health Science Center at Houston,undefined
[6] Matsuyama Shimin Hospital,undefined
[7] Hamamatsu University School of Medicine,undefined
来源
Brain Tumor Pathology | 2022年 / 39卷
关键词
Oncolytic virus; Immune cells; Glioma;
D O I
暂无
中图分类号
学科分类号
摘要
Despite current progress in treatment, glioblastoma (GBM) remains a lethal primary malignant tumor of the central nervous system. Although immunotherapy has recently achieved remarkable survival effectiveness in multiple malignancies, none of the immune checkpoint inhibitors (ICIs) for GBM have shown anti-tumor efficacy in clinical trials. GBM has a characteristic immunosuppressive tumor microenvironment (TME) that results in the failure of ICIs. Oncolytic herpes simplex virotherapy (oHSV) is the most advanced United States Food and Drug Administration-approved virotherapy for advanced metastatic melanoma patients. Recently, another oHSV, Delytact®, was granted conditional approval in Japan against GBM, highlighting it as a promising treatment. Since oncolytic virotherapy can recruit abundant immune cells and modify the immune TME, oncolytic virotherapy for immunologically cold GBM will be an attractive therapeutic option for GBM. However, as these immune cells have roles in both anti-tumor and anti-viral immunity, fine-tuning of the TME using oncolytic virotherapy will be important to maximize the therapeutic efficacy. In this review, we discuss the current knowledge of oHSV, with a focus on the role of immune cells as friend or foe in oncolytic virotherapy.
引用
收藏
页码:57 / 64
页数:7
相关论文
共 231 条
  • [1] Ostrom QT(2019)CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016 Neuro Oncol 21 v1-v100
  • [2] Cioffi G(2021)The 2021 WHO classification of tumors of the central nervous system: a summary Neuro Oncol 23 1231-1251
  • [3] Gittleman H(2019)Dynamic reorganization of microtubule and glioma invasion Acta Med Okayama 73 285-297
  • [4] Louis DN(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
  • [5] Perry A(2017)Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial JAMA 318 2306-2316
  • [6] Wesseling P(2020)Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial JAMA Oncol 6 1003-1010
  • [7] Otani Y(2020)Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes Cell 181 1626-1642.e1620
  • [8] Ichikawa T(2020)Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma Nat Med 26 39-46
  • [9] Kurozumi K(2019)Actively personalized vaccination trial for newly diagnosed glioblastoma Nature 565 240-245
  • [10] Stupp R(2019)Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial Nature 565 234-239